Nicolas Villanueva, MD

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss the future of personalized treatment in EGFR-mutant NSCLC.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss how antibody-drug conjugates are shaping treatment strategies after progression.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss treatment sequencing following progression on intensified regimens.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, outline the role of ctDNA in guiding treatment decisions.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, examine how high-risk disease is defined and applied in clinical practice.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, examine how overall survival data from recent trials are influencing treatment decisions.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss key inflection points in frontline treatment of EGFR-mutant NSCLC.